Eli Lilly hits record high after earnings, Mounjaro hype. Here's what the pros are saying

Jim Cramer, Jared Holz of Mizuho Securities, Bryn Talkington of Requisite Capital Management and Sarat Sethi of DCLA discussed Eli Lilly after the company beat earnings and revenue estimates for the second quarter and raised its full-year guidance.